US Stock Futures Signal Higher Start On Wall Street

Pre-open movers US stock futures traded higher in early pre-market trade. Data on weekly jobless claims will be released at 8:30 a.m. ET, while the Markit PMI services index for December will be released at 9:45 a.m. ET. The general conditions index of the Philadelphia Fed's Survey for December and the Conference Board's index of leading indicators for November will be released at 10:00 a.m. ET. Futures for the Dow Jones Industrial Average jumped 181 points to 17,473.00, while the Standard & Poor's 500 index futures rose 22.20 points to 2,030.40. Futures for the Nasdaq 100 index climbed 53.25 points to 4,212.75. A Peek Into Global Markets European markets were higher today, with the Spanish Ibex Index gaining 2.69%, STOXX Europe 600 Index rising 2.07%. German DAX 30 index climbed 2.08%, French CAC 40 Index gained 2.57% and London's FTSE 100 Index rose 0.98%. In Asian markets, Japan's Nikkei Stock Average rose 2.32%, Hong Kong's Hang Seng Index climbed 1.09%, China's Shanghai Composite Index fell 0.11% and India's Sensex jumped 1.56%. Broker Recommendation Analysts at Longbow Research upgraded Joy Global, Inc. JOY from Underperform to Neutral. The price target for Joy Global is set to $50. Joy Global's shares closed at $46.14 yesterday. Breaking news

• Winnebago Industries, Inc. WGO reported weaker-than-expected fiscal first-quarter earnings. To read the full news, click here.
• Akers Biosciences, Inc. AKER has entered into its first European distribution agreements since the installment of its international vice president in August 2014. To read the full news, click here.
• TetraLogic Pharmaceuticals Corporation TLOG today announced the initiation of a randomized Phase 2 clinical trial of SHAPE in subjects with early stage cutaneous T cell lymphoma ("CTCL"). To read the full news, click here.
• BioCryst Pharmaceuticals, Inc., BCRX today announced that it has dosed the first patient in OPuS-2 (Oral ProphylaxiS-2), a blinded, randomized, placebo-controlled clinical trial of orally-administered BCX4161 in patients with hereditary angioedema (HAE). To read the full news, click here.